Gamida doses first subject in Phase I/II cell therapy trial for lymphomas

Gamida doses first subject in Phase I/II cell therapy trial for lymphomas

Submitted by admin on August 11, 2022 - 12:17pm
Source: 
Clinical Trials Arena
News Tags: 
Gamida Cell
natural killer cell therapy
GDA-201
diffuse large B-cell lymphoma
follicular B-cell non-Hodgkin lymphoma
Headline: 
Gamida doses first subject in Phase I/II cell therapy trial for lymphomas
snippet: 

Gamida Cell has dosed the first subject in the Phase I/II clinical trial of natural killer (NK) cell therapy candidate GDA-201 to treat patients with follicular and diffuse large B cell lymphomas (FL and DLBCL).

Do Not Allow Advertisers to Use My Personal information